- Previous Close
25.27 - Open
25.45 - Bid 26.33 x --
- Ask 26.34 x --
- Day's Range
25.27 - 26.63 - 52 Week Range
21.33 - 31.18 - Volume
20,453,380 - Avg. Volume
5,865,756 - Market Cap (intraday)
11.35B - Beta (5Y Monthly) --
- PE Ratio (TTM)
21.41 - EPS (TTM)
1.23 - Earnings Date --
- Forward Dividend & Yield 0.40 (1.52%)
- Ex-Dividend Date Jul 26, 2024
- 1y Target Est
--
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the manufacturing and sale of Chinese and Western medicines primarily in China. The company provides functional cosmetics, such as eye care, eye daily necessities, facial and body cleaning, and care products; functional care products include infant paper, infant skin care, feminine products, etc.; functional foods, including moisturizing the intestines, promoting digestion, and nourishing the kidneys. It also offers foundation and dietary supplements; medical products comprising anorectal postoperative care, daily electronic auxiliary products, eye device care, disinfection and sterilization, etc. In addition, the company is involved in the development, production, and sale of pharmaceutical products; retail and wholesale of medical devices and drugs; provision of hospital medical and management service; and hospital operations. It sells its products through online stores. Mayinglong Pharmaceutical Group Co., Ltd., was founded in 1582 and is headquartered in Wuhan, China.
www.mayinglong.cn--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600993.SS
View MorePerformance Overview: 600993.SS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600993.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600993.SS
View MoreValuation Measures
Market Cap
11.35B
Enterprise Value
8.43B
Trailing P/E
21.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.03
Price/Book (mrq)
2.79
Enterprise Value/Revenue
2.26
Enterprise Value/EBITDA
11.30
Financial Highlights
Profitability and Income Statement
Profit Margin
14.17%
Return on Assets (ttm)
7.73%
Return on Equity (ttm)
13.59%
Revenue (ttm)
3.73B
Net Income Avi to Common (ttm)
528.09M
Diluted EPS (ttm)
1.23
Balance Sheet and Cash Flow
Total Cash (mrq)
3.16B
Total Debt/Equity (mrq)
5.57%
Levered Free Cash Flow (ttm)
216.13M